GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hard to Treat Diseases Inc (OTCPK:HTDS) » Definitions » 3-Year EBITDA Growth Rate

Hard to Treat Diseases (Hard to Treat Diseases) 3-Year EBITDA Growth Rate : 0.00% (As of . 20)


View and export this data going back to . Start your Free Trial

What is Hard to Treat Diseases 3-Year EBITDA Growth Rate?

Hard to Treat Diseases's EBITDA per Share for the three months ended in . 20 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of Hard to Treat Diseases's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Hard to Treat Diseases's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hard to Treat Diseases's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hard to Treat Diseases's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hard to Treat Diseases's 3-Year EBITDA Growth Rate falls into.



Hard to Treat Diseases 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Hard to Treat Diseases  (OTCPK:HTDS) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Hard to Treat Diseases 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hard to Treat Diseases's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hard to Treat Diseases (Hard to Treat Diseases) Business Description

Traded in Other Exchanges
N/A
Address
2655 Ulmerton Road, No. 338, Clearwater, FL, USA, 33762
Hard to Treat Diseases Inc operates medical and cosmetics company in Europe, and Mainland China. It is s also in the process of developing its own stem cell bank.

Hard to Treat Diseases (Hard to Treat Diseases) Headlines

No Headlines